Printer Friendly

MARION MERRELL DOW WITHDRAWS PLANNED SALE OF U.S. BIOSCIENCE COMMON STOCK

 MARION MERRELL DOW WITHDRAWS PLANNED SALE OF
 U.S. BIOSCIENCE COMMON STOCK
 KANSAS CITY, Mo., April 7 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today announced it has withdrawn a previously disclosed request for registration and sale of all the common stock it holds in U.S. Bioscience Inc.
 The withdrawal of the request is the result of an agreement among the company, U.S. Bioscience, U.S. Healthcare and other parties. The company agreed to withdraw its request for registration in view of changes in the market since the time of the request and in order to enable U.S. Healthcare to complete the previously announced distribution of the U.S. Bioscience shares it owns to its shareholders.
 Under the agreement, Marion Merrell Dow can renew its registration request covering the proposed sale of U.S. Bioscience stock following the U.S. Healthcare distribution. The company said any decision to renew the request and sell all or part of its U.S. Bioscience stock would depend on general economic and market conditions and other factors at that time.
 Marion Merrell Dow is a global pharmaceutical firm whose business activities focus on the discovery, development, manufacturing and marketing of prescription and over-the-counter pharmaceutical products. The company markets more than 140 products, predominantly in the United States and seven other countries in North America, Europe and the Pacific Basin.
 -0- 4/7/92
 /CONTACT: David M. Thompson or Richard M. Johnson both of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc.; U.S. Bioscience Inc.; U.S. Healthcare ST: Missouri IN: MTC SU:


BB -- DV004 -- 5829 04/07/92 12:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:273
Previous Article:BROWNSVILLE (TEXAS) UTILITIES SYSTEM PRIORITY BONDS RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:ST. PAUL FIRE AND MARINE INSURANCE COMPANY STRENGTHENS CANADIAN OPERATIONS


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC AND MARION MERRELL DOW COMPLETE $18 MILLION STOCK PURCHASE PORTION OF ALLERVAX COMMERCIALIZATION AGREEMENT
MARION MERRELL DOW STATEMENT ON U.S. BIOSCIENCE
U.S. HEALTHCARE ANNOUNCES INTENT TO DIVIDEND ITS U.S. BIOSCIENCE HOLDINGS
MARION MERRELL DOW ANNOUNCES PLAN FOR SECONDARY OFFERING OF COMMON STOCK
U.S. BIOSCIENCE REACHES AGREEMENT WITH MARION MERRELL DOW AND U.S. HEALTHCARE REGARDING STOCK DISTRIBUTION
U.S. HEALTHCARE ANNOUNCES AGREEMENT TO DISTRIBUTE U.S. BIOSCIENCE SHARES
MARION MERRELL DOW REPORTS STRONG FIRST-QUARTER SALES, EARNINGS GROWTH
MARION MERRELL DOW REPORTS STRONG FIRST-QUARTER SALES, EARNINGS GROWTH
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters